Recently, Novartis China's drug for the treatment of non-small cell lung cancer, Torida (Camatinib Hydrochloride Tablets), has been approved by the National Medical Products Administration of China for use in adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) carrying mesenchymal epithelial transition factor (MET) exon 14 jump mutation who have not undergone systematic treatment. In China, the incidence rate and mortality of lung cancer rank first among all types of cancer. In 2022, 1060600 new cases of lung cancer will occur, accounting for 22.0% of all malignant tumors, and the mortality rate will account for 28.5% of all malignant tumor deaths. In lung cancer, the proportion of non-small cell lung cancer (NSCLC) patients is as high as 80-85%, and there are multiple driver gene mutations. Among them, METex14 jump mutation is one of the key driving genes and has been proven to be an independent carcinogenic factor in non-small cell lung cancer. In non-small cell lung cancer patients, the METex14 jump mutation rate is about 1% -3%, often occurring in an older population (median age of 72.5 years), and traditional treatment methods such as chemotherapy and immunotherapy have limited effectiveness. As the disease is caused by abnormal activation of the MET signaling pathway, MET inhibitors have become an important treatment for METex14 jump mutations. Torida is an oral specific MET receptor tyrosine kinase inhibitor. Professor Wu Yilong from Guangdong Provincial People's Hospital said, "Although METex14 is a rare target for lung cancer, it also affects a large population in China, and there is an urgent need for treatment for this mutation. The approval of Camatinib hydrochloride tablets in China has opened a new chapter in the treatment of non-small cell lung cancer in China, bringing new hope for treatment to the vast number of patients." It is worth mentioning that in order to enable Chinese patients to use innovative therapies as soon as possible, Toride had already entered the second batch of clinical imported drugs and medical devices from Hong Kong and Macao in the Guangdong Hong Kong Macao Greater Bay Area in early 2022 before its official approval, and was in a specific medical tourism pilot area in Boao Lecheng International Medical Tourism Pilot Zone, Hainan. Medical institutions urgently need to be applied in clinical practice. (Lai Xin She)